Lama-84 Cells

LAMA-84 is a human cell line derived from the peripheral blood of a patient with chronic myeloid leukemia (CML) in blast crisis. This cell line is characterized by the presence of the Philadelphia chromosome, which results in the BCR-ABL fusion gene, a hallmark of CML. The BCR-ABL oncogene is known for its role in increasing tyrosine kinase activity, which promotes various signaling pathways leading to uncontrolled cell proliferation and resistance to apoptosis. LAMA-84 cells are thus an invaluable model for studying the molecular mechanisms of CML progression and for evaluating the efficacy of tyrosine kinase inhibitors (TKIs) in a pre-clinical setting.

In research, LAMA-84 has been extensively used to understand the biology of CML, especially in the context of drug resistance and disease evolution. Studies involving this cell line have helped in elucidating the cellular responses to different generations of TKIs, such as imatinib, dasatinib, and nilotinib. Moreover, LAMA-84 has contributed to the investigation of new therapeutic strategies aimed at overcoming TKI resistance, including the testing of combination therapies that target other signaling pathways synergistically affected by the BCR-ABL fusion protein.